米氮平
体重增加
抗抑郁药
医学
不利影响
减肥
安非他酮
重量变化
食欲
依西酞普兰
精神科
体重
内科学
肥胖
焦虑
戒烟
病理
作者
Hartej Gill,Barjot Gill,Sabine El‐Halabi,David Chen‐Li,Orly Lipsitz,Joshua D. Rosenblat,Tamsyn E. Van Rheenen,Nelson B. Rodrigues,Rodrigo B. Mansur,Amna Majeed,Leanna M.W. Lui,Flora Nasri,Yena Lee,Roger S. McIntyre
出处
期刊:Obesity
[Wiley]
日期:2020-10-06
卷期号:28 (11): 2064-2072
被引量:135
摘要
Antidepressant medications are the first‐line treatment option for moderate to severe major depressive disorder. However, most antidepressants have numerous documented adverse events, including cardiometabolic effects and weight gain, which are major public health concerns. Antidepressant agents provide varying risk of associated weight gain, including significant within‐class differences. Some agents, such as mirtazapine, show significant levels of weight gain, while others, such as bupropion, demonstrate weight‐loss effects. Current findings suggest the role of histamine and serotonin off‐target appetite‐promoting pathways in adverse weight‐gain effects. Therefore, controlling for undesired weight effects is an important consideration for the selection of antidepressants.
科研通智能强力驱动
Strongly Powered by AbleSci AI